

VENTRUS BIOSCIENCES INC
Form 8-K
January 07, 2011

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 7, 2011

VENTRUS BIOSCIENCES, INC.
(Exact name of registrant as specified in its charter)

Delaware 001-35005 20-8729264
(State or other (Commission (IRS
jurisdiction of File Employer
incorporation) Number) ID Number)

787 7th 10019
Avenue,
48th
Floor,
New
York,
New
York
(Address (Zip
of Code)
principal
executive
offices)

Registrant's telephone number, including area code (212) 554-4300

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Edgar Filing: VENTRUS BIOSCIENCES INC - Form 8-K

- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

Item 8.01. Other Events.

On January 7, 2011, Ventrus Biosciences, Inc. (the “Company”) issued a press release announcing that the underwriters of the Company’s initial public offering exercised their over-allotment option to purchase an additional 435,000 shares at \$6.00 per share. A copy of this press release is attached.

Item 9.01. Financial Statements and Exhibits.

(d)	Exhibits
Exhibit No.	Description
99.1	Press release dated January 7, 2011 announcing that the underwriters of the Company’s initial public offering exercised their over-allotment option to purchase an additional 435,000 shares at \$6.00 per share.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

VENTRUS BIOSCIENCES, INC.

Date: January 7, 2011

/s/ David J. Barrett
David J. Barrett, Chief Financial Officer